Histogen (NASDAQ:HSTO) Lifted to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Histogen (NASDAQ:HSTO) from a sell rating to a hold rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “Histogen Inc. is a regenerative medicine company. It engages in developing patented technologies which replace and regenerates tissues in the body. The company’s technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells, developing therapeutic products. Histogen Inc., formerly known as Conatus Pharmaceuticals Inc., is based in San Diego, United States. “

Shares of HSTO opened at $0.27 on Wednesday. The stock has a 50 day moving average of $0.44 and a 200 day moving average of $0.69. Histogen has a 12 month low of $0.26 and a 12 month high of $1.98.

Histogen (NASDAQ:HSTO) last announced its quarterly earnings data on Wednesday, November 10th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. Histogen had a negative return on equity of 84.22% and a negative net margin of 1,018.14%. The business had revenue of $0.59 million during the quarter. During the same period last year, the company posted ($0.27) earnings per share. On average, equities research analysts predict that Histogen will post -0.43 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in HSTO. Goldman Sachs Group Inc. bought a new position in Histogen during the second quarter valued at $34,000. Two Sigma Securities LLC boosted its holdings in shares of Histogen by 124.7% in the third quarter. Two Sigma Securities LLC now owns 52,289 shares of the company’s stock worth $40,000 after acquiring an additional 29,019 shares during the period. Newman Dignan & Sheerar Inc. bought a new position in shares of Histogen in the third quarter worth $40,000. Virtu Financial LLC bought a new position in shares of Histogen in the second quarter worth $69,000. Finally, Millennium Management LLC boosted its holdings in shares of Histogen by 265.7% in the second quarter. Millennium Management LLC now owns 71,398 shares of the company’s stock worth $78,000 after acquiring an additional 51,876 shares during the period. 6.81% of the stock is owned by institutional investors and hedge funds.

About Histogen

Histogen, Inc engages in the development of potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. It focuses in Human Multipotent Cell Conditioned Media, Human Extracellular Matrix, and Hair Stimulating Complex. The company was founded by Steven J.

Featured Article: Buyback

Get a free copy of the Zacks research report on Histogen (HSTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Histogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogen and related companies with MarketBeat.com's FREE daily email newsletter.